Loading...

Sonoma Pharmaceuticals Inc
NASDAQ:SNOA

Watchlist Manager
Sonoma Pharmaceuticals Inc Logo
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Watchlist
Price: 1.71 USD +4.91% Market Closed
Updated: Nov 30, 2022

Intrinsic Value

SNOA doesn't have a meaningful market cap.

The intrinsic value of one SNOA stock under the Base Case scenario is 5.21 USD. Compared to the current market price of 1.71 USD, Sonoma Pharmaceuticals Inc is Undervalued by 67%.

The Intrinsic Value is calculated as the average of the two valuation methods:

SNOA Intrinsic Value
Base Case
5.21 USD
Undervaluation 67%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

SNOA Profitability Score
Profitability Due Diligence

Sonoma Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
20/100
Profitability
Score

Sonoma Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

SNOA Solvency Score
Solvency Due Diligence

Sonoma Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Long-Term Liabilities
Short-Term Liabilities
50/100
Solvency
Score

Sonoma Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
34%
Gross Margin
-43%
Operating Margin
-46%
Net Margin
-37%
FCF Margin
-63%
ROE
-51%
ROIC
Other

SNOA Capital Structure
Sonoma Pharmaceuticals Inc

Market Capitalization 5.3M USD
Total Debt 244k USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 3.4M USD
Short-Term Investments 0 USD
Enterprise Value 2.2M USD

Wall St
Price Targets

SNOA Price Targets Summary
Sonoma Pharmaceuticals Inc

Wall Street analysts forecast SNOA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SNOA is 9 USD .

Lowest
Price Target
Not Available
Average
Price Target
9 USD
426% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

SNOA Competitors
Sonoma Pharmaceuticals Inc

SNOA Suppliers & Customers
Sonoma Pharmaceuticals Inc

There is no information about
Sonoma Pharmaceuticals Inc
key suppliers

Sonoma Pharmaceuticals Inc has 2 key customers from 1 countries and 2 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Pharmaceuticals industry.

Customers Map

Ownership

SNOA Shareholders
Major Shareholders

Insiders own a significant part of the company.

Top 25 shareholders own 38.07% of the company. Insiders own 33.58%. The biggest insider is Sandford Frederick J (CEO and Interim CFO), who owns 14.53% of Sonoma Pharmaceuticals Inc.

Insiders
33.58%
Institutions
4.49%
Other
61.93%
Insiders
33.58%
Sandford Frederick J
CEO and Interim CFO
Ownership
14.527%
Market Value
770k USD
Shares
450 000
Birnbaum Jay E
Director
Ownership
2.7299%
Market Value
145k USD
Shares
84 563
Mclaughlin John
Director
Ownership
2.6465%
Market Value
140k USD
Shares
81 980
Thornton Bruce
COO
Ownership
2.4787%
Market Value
131k USD
Shares
76 781
Trombly Amy Moss
Chief Executive Officer
Ownership
2.3775%
Market Value
126k USD
Shares
73 648
Dvonch Jerome J
Chief Financial Officer
Ownership
1.8652%
Market Value
98.8k USD
Shares
57 777
Harrison Russell Joseph
Director
Ownership
1.5018%
Market Value
79.5k USD
Shares
46 520
Barbari Sharon Surrey
Director
Ownership
1.4016%
Market Value
74.2k USD
Shares
43 417
Schutz James J
Former CEO and Former Director
Ownership
1.1576%
Market Value
61.3k USD
Shares
35 858
Miller Robert E
Former CFO
Ownership
1.1407%
Market Value
60.4k USD
Shares
35 336
Weigerstorfer Philippe
Director
Ownership
0.9685%
Market Value
51.3k USD
Shares
30 000
Dal Poggetto John
Chief Financial Officer
Ownership
0.7004%
Market Value
37.1k USD
Shares
21 697
Edwards Robert Grant
Chief Financial Officer
Ownership
0.0842%
Market Value
4.5k USD
Shares
2 609
Institutions
4.49%
Back

SNOA Insider Trading
Buy and sell transactions by insiders

Sonoma Pharmaceuticals Inc insiders have not made purchase/sale transactions in the past 12 months.

During the last 12 months Sonoma Pharmaceuticals Inc insiders have not bought any shares, and have not sold any shares. The last transaction was made on Nov 30, 2022 by Miller Robert E (Former CFO), who bought 4.9k USD worth of SNOA shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
N/A
N/A
6 Months
N/A
N/A
N/A
9 Months
N/A
N/A
N/A
12 Months
N/A
N/A
N/A
Purchases
41
Sales
8
Why is insider trading important?

Shareholder Return

SNOA Price
Sonoma Pharmaceuticals Inc

1M 1M
-14%
6M 6M
-50%
1Y 1Y
-68%
3Y 3Y
-57%
5Y 5Y
-96%
Annual Price Range
1.71
52w Low
1.63
52w High
5.3
Price Metrics
Average Annual Return -10.73%
Standard Deviation of Annual Returns 63.82%
Max Drawdown -97%

Company Profile

Sonoma Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

5.3M USD

Dividend Yield

0%

Description

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company is headquartered in Woodstock, Georgia and currently employs 13 full-time employees. The company went IPO on 2007-01-26. The firm's product offerings include Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Its products are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. The company also has its office dispense products, such as Lasercyn Dermal Spray, Lasercyn Post Procedure Gel and Regenacyn Advanced Scar Management. The firm sells its products either directly or via partners in approximately 54 countries across the world. Its subsidiaries include Aquamed Technologies, Inc., Oculus Technologies of Mexico, S.A. de C.V. and Sonoma Pharmaceuticals Netherlands B.V.

Contact

GEORGIA
Woodstock
645 Molly Lane, Suite 150
+18007599305.0
https://sonomapharma.com/

IPO

2007-01-26

Employees

13

Officers

CEO, Pres & Director
Ms. Amy M. Trombly
Chief Financial Officer
Mr. Jerome Dvonch
COO & Corp. Sec.
Mr. Bruce Thornton
Exec. VP of R&D
Dr. Robert Northey
Assistant Controller
Ms. Victoria Covel

See Also

Similar Stocks
What is the Intrinsic Value of one SNOA stock?

The intrinsic value of one SNOA stock under the Base Case scenario is 5.21 USD.

Is SNOA stock undervalued or overvalued?

Compared to the current market price of 1.71 USD, Sonoma Pharmaceuticals Inc is Undervalued by 67%.